Luca Costanzo,
Department of Cardiovascular Disease, Angiology Unit, San Marco Hospital A.O.U. ”Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Giacomo Failla,
Department of Cardiovascular Disease, Angiology Unit, San Marco Hospital A.O.U. ”Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Simona A. Grasso,
Department of Anesthesia and Intensive Care, AOU Policlinico Vittorio Emanuele, Catania, Italy
Francesco P. Palumbo,
Surgery Unit, Villa Fiorita Clinic, Prato, Italy
Giorgio Ardita,
Department of Cardiovascular Disease, Angiology Unit, San Marco Hospital A.O.U. ”Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Luigi Di-Pino,
Department of Cardiovascular Disease, Cardiology and Angiology C.A.S.T., A.O.U. ”Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Francesco Mugno,
Department of Cardiovascular Disease, Angiology Unit, San Marco Hospital A.O.U. ”Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Paolo Finocchiaro,
Department of Cardiovascular Disease, Angiology Unit, San Marco Hospital A.O.U. ”Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Leonardo Aluigi,
Angiology, Care Unit Villalba, Bologna, Italy
Pier Luigi-Antignani,
Vascular center, Nuova Villa Claudia, Rome, Italy


The development of coagulopathy is emerging as one of the most significant poor prognostic features in coronavirus disease (COVID)-19 pneumopathy. D-dimer, a protein product of fibrin degradation, has been found elevated in the most severe cases and correlated to mortality. Potentially involved factors in the impairment of coagulation caused by viral infection include the dysregulated inflammatory response, platelet, and endothelial dysfunction with impaired fibrinolysis. Heparin is an anticoagulant molecule that also showed anti-inflammatory properties and a potential antiviral effect. The use of low-molecular- weight heparin could prevent thromboembolic complications in COVID-19 pneumopathy. However, the correct timing of prophylaxis according to the stage of COVID-19 disease and the appropriate therapeutic dosage to use in severe cases needs further researches.



Keywords: Coronavirus disease-19. Thrombosis. Coagulopathy. D-dimer. Low-molecular-weight heparin.